| D68 | Willingness to be vaccinated for COVID-19 among people with HIV in the United States: results from a national survey | E-poster | Living with HIV and co-infections and/or co-morbidities |
| D68 | COVID-19 vaccine hesitancy and associated factors among people with HIV in the United States: findings from a national survey | E-poster | Living with HIV and co-infections and/or co-morbidities |
| B39 | Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir + rilpivirine for treatment in adults with HIV-1 infection (ITT-E population) | On-demand oral abstract session | Long-acting agents and other drug delivery systems |
| B39 | Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE) | Oral abstract session with live Q&A | Long-acting agents and other drug delivery systems |
| C25 | Characterizing the effect of the COVID-19 pandemic on PEPFAR-supported voluntary medical male circumcision services, 2020 | E-poster | Male circumcision |
| C25 | Changes in the quality of voluntary medical male circumcision services in selected districts of the Mpumalanga, Eastern Cape, Free State and North West Provinces of South Africa | E-poster | Male circumcision |
| C25 | HIV Prevention in COVID-19 lockdown: The impact of suspending VMMC in SA and the subsequent effects on HIV transmission dynamics | E-poster | Male circumcision |
| C25 | Demand creation and voluntary medical male circumcision during COVID-19 pandemic | E-poster | Male circumcision |
| C25 | Association between medical male circumcision and HIV risk compensation among heterosexual men: a systematic review and meta-analysis | E-poster | Male circumcision |
| C25 | Experience with ShangRing circumcision in Malawi voluntary medical male circumcision program | E-poster | Male circumcision |